Constitutive expression of human immunodeficiency virus Type I (HIV-1) tat gene inhibits IL-2 and IL-2 receptor (IL-2R) expression in a human CD4+ T (H-9) cell line (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Constitutive expression of human immunodeficiency virus Type I (HIV-1) tat gene inhibits IL-2 and IL-2 receptor (IL-2R) expression in a human CD4+ T (H-9) cell line (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A2846 1994. Unique Identifier : AIDSLINE ICDB/95604531
Leland P; Aggarwal BB; Puri RK; Lab. of Molecular Tumor Biology, CBER, FDA, Bethesda, MD 20892

Abstract: HIV-1 tat, a transactivator of the HIV long terminal repeat, is essential for HIV replication and causes inhibition of antigen-mediated T-cell proliferation. To understand the mechanism of inhibition of T cell proliferation, we have investigated the regulation of IL-2 production and IL2R expression on a human CD4+ T cell line transfected with HIV-1 tat gene. When cells were activated by mitogens, a significant decrease in both IL-2 mRNA and protein was observed in tat transfected cells compared to control. Similarly, mitogen induced IL-2R alpha mRNA and surface expression was significantly decreased in tat transfected cells compared to control cells. IL-4R expression was unaltered by tat transfection indicating a specific cellular effect rather than a generalized phenomenon. Due to the central role of IL-2 in immunoregulation, our data suggest that immunosuppressive effects of HIV-1 tat may be mediated at least in part through the inhibition of IL-2 production and IL-2R expression.

Keywords: Cell Division Cell Line CD4-Positive T-Lymphocytes/CYTOLOGY/*METABOLISM *Gene Expression/DRUG EFFECTS Gene Products, tat/*GENETICS/IMMUNOLOGY Immunosuppression Interleukin-2/*GENETICS/METABOLISM Mitogens Receptors, Interleukin-2/*GENETICS/METABOLISM RNA, Messenger/METABOLISM ABSTRACT
950330
M9530839

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .